DHODH-IN-23
Modify Date: 2024-04-03 10:13:33
DHODH-IN-23 structure
|
Common Name | DHODH-IN-23 | ||
|---|---|---|---|---|
| CAS Number | 1346705-53-0 | Molecular Weight | 441.88 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C24H21ClFNO4 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of DHODH-IN-23DHODH-IN-23 (Compound A) is an orally active DHODH inhibitor that can be used for the research of cancer[1]. |
| Name | DHODH-IN-23 |
|---|
| Description | DHODH-IN-23 (Compound A) is an orally active DHODH inhibitor that can be used for the research of cancer[1]. |
|---|---|
| Related Catalog | |
| In Vitro | DHODH-IN-23 (Compound A; 72 h) 抑制急性髓系白血病细胞增殖[1]。 DHODH-IN-23 (0.1-3 μM; 72 h) 诱导 THP-1 细胞中 CDllb 的表达[1]。 Cell Proliferation Assay[1] Cell Line: U937, HL-60, THP-1, KG-1 and MV411 Concentration: Incubation Time: 72 h Result: Inhibited cell growth with GI50s of 2.4, 2.5, 2.5, 3.5 and 7.6 μM against U937, THP-1, MV411 HL-60 and KG-1, respectively. RT-PCR[1] Cell Line: THP-1 cells Concentration: 72 h Incubation Time: 0.1, 1 and 3 μM Result: Induced CDllb mRNA expression. |
| In Vivo | DHODH-IN-23 (Compound A; 30 mg/kg; oral; twice daily for 21 days) 在 MV411 小鼠异种移植模型中显示出抗肿瘤活性[1]。 Animal Model: MV411 mouse xenograft model[1] Dosage: 30 mg/kg Administration: Oral administration, twice daily for 21 days Result: Demonstrated significant anti-tumor activity both as a single agent and in combination with Cytarabine (HY-13605) at 20 mg/kg with tumor growth inhibitions of 37 and 73% respectively. |
| References |
| Molecular Formula | C24H21ClFNO4 |
|---|---|
| Molecular Weight | 441.88 |